Research

Highlights from among 140+ original, peer-reviewed articles on PubMed

Research: Education

Mentees of Dr. Hadland are identified with italicized text and asterisks**

Bagley SM, Gai MJ, Earlywine JJ, Schoenberger SF, Hadland SE (Co-Senior Author), Barocas JA. Incidence and Characteristics of Nonfatal Opioid Overdose Among Youths Aged 11 to 24 Years by Sex. JAMA Netw Open. 2020 Dec 1;3(12):e2030201. PMID: 33331919. PMC7747019.

Lim JK**, Earlywine JJ, Bagley SM, Marshall BDL, Hadland SE. Polysubstance Involvement in Opioid Overdose Deaths in Adolescents and Young Adults, 1999-2018. JAMA Pediatr. 2020 Nov 23. doi: 10.1001/jamapediatrics.2020.5035. Online ahead of print. PMID: 33226412. PMC7684514.

Earlywine JJ**, Hadland SE, Raifman J. State-level prescription drug monitoring program mandates and adolescent injection drug use in the United States, 1995-2017: A difference-in-differences analysis. PLoS Med. 2020 Sep 25;17(9):e1003272. PMID: 32976539. PMC7518580.

Hadland SE, Jent VA, Alinsky RH**, Marshall BDL, Mauro PM, Cerdá M. Opioid Use Disorder Treatment Facilities With Programs for Special Populations. Am J Prev Med. 2020;pii: S0749-3797(20)30178-1. PMID: 32448551. PMC1591965.

Hadland SE, Cerdá M, Earlywine JJ, Krieger MS, Anderson TS, Marshall BDL. Analysis of Pharmaceutical Industry Marketing of Stimulants, 2014 Through 2018. JAMA Pediatr. 2020 Jan 21. doi: 10.1001/jamapediatrics.2019.5526. [Epub ahead of print] PMID: 31961384. PMC6990909.

Alinsky RH**, Zima BT, Rodean J, Matson PA, Larochelle MR, Adger H Jr, Bagley SM, Hadland SE. Receipt of Addiction Treatment After Opioid Overdose Among Medicaid-Enrolled Adolescents and Young Adults. JAMA Pediatr. 2020;174(3):e195183. PMID: 31905233. PMC6990723.

Anderson TS**, Marshall BDL, Krieger MS, Cerdá M, Hadland SE. Financial Payments to Teaching Hospitals by Companies Marketing Opioids. J Gen Intern Med. 2019 Dec 17. doi: 10.1007/s11606-019-05596-1 [Epub ahead of print] PMID: 31848860. PMC7572903.

Chadi N**, Rodean J, Earlywine JJ, Zima BT, Bagley SM, Levy S, Hadland SE. Treatment for Nicotine Use Disorder Among Medicaid-Enrolled Adolescents and Young Adults. JAMA Pediatr. 2019;173(11):1103-5. PMID: 31545354. PMC6763988.

Hadland SE, Rivera-Aguirre A, Marshall BDL, Cerdá M. Association of Pharmaceutical Industry Marketing of Opioid Products With Mortality From Opioid-Related Overdoses. JAMA Netw Open. 2019 Jan 4;2(1):e186007. PMID: 30657529. PMC6484875.

Hadland SE, Bagley SM, Rodean J, Silverstein M, Levy S, Larochelle MR, Samet JH, Zima BT. Receipt of Timely Addiction Treatment and Association of Early Medication Treatment With Retention in Care Among Youths With Opioid Use Disorder. JAMA Pediatr. 2018;172(11):1029-1037. PMID: 30208470. PMC6218311.

Hadland SE, Cerdá M, Li Y, Krieger MS, Marshall BD. Pharmaceutical Industry Marketing of Opioid Products to Physicians and Subsequent Opioid Prescribing. JAMA Intern Med. 2018;178(6):861-863. PMID: 29799955. PMC6145750. Author reply: Hadland et al. JAMA Intern Med. 2018;178(10):1426-1427.

Hadland SE, Park TW, Bagley SM. Stigma associated with medication treatment for young adults with opioid use disorder: a case series. Addict Sci Clin Pract. 2018 May 7;13(1):15. PMID: 29730987. PMC5937046.

Hadland SE, Krieger MS, Marshall BD. Industry Payments to Physicians Involving Opioids, 2013-2015. Am J Public Health. 2017;107(9):1493-1495. PMID: 28787210. PMC5551628.

Hadland SE, Wharam JF, Schuster MA, Zhang F, Samet JH, Larochelle MR. Trends in Receipt of Buprenorphine and Naltrexone for Opioid Use Disorder among Adolescents and Young Adults, 2001-2014. JAMA Pediatr. 2017;171(8):747-755. PMID: 28628701. PMC5649381.

Hadland SE, Copelas SH, Harris SK. Trajectories of Substance Use Frequency among Adolescents Seen in Primary Care: Implications for Screening. J Pediatr. 2017;pii:S0022-3476(17)30143-9. PMID: 28196680. PMC5403571.

Hadland SE, Xuan Z, Sarda V, Blanchette J, Swahn MH, Heeren TC, Voas RB, Naimi TS. Alcohol Policies and Alcohol-Related Motor Vehicle Crash Fatalities Among Young People in the US. Pediatrics. 2017;139(3). pii: e20163037. PMID: 28193794. PMC5330403.

Hadland SE, Wood E, Dong H, Marshall BD, Kerr T, Montaner JS, DeBeck K. Suicide attempts and childhood maltreatment among street youth: a prospective cohort study. Pediatrics, 2015;136(3):440-9. PMID: 26240210. PMC4552091

Hadland SE, DeBeck K, Kerr T, Nguyen P, Simo A, Montaner JS, Wood E. Use of a medically supervised injection facility among street youth. J Adolesc Health, 2014;55(5):684-9. PMID: 24925493. PMC4209311.

Hadland SE, Harris SK. Youth marijuana use: State of the science for the practicing clinician. Curr Opin Pediatr, 2014;26(4):420-7. PMID: 24914878. PMC4138809

Google Scholar Analytics

As of February 2021

_Scott-E-Hadland-MD-MPH-MS_-_Google-Scho

Research: Image

Research

Mentees of Dr. Hadland are identified with italicized text and asterisks**

Bagley SM, Gai MJ, Earlywine JJ, Schoenberger SF, Hadland SE (Co-Senior Author), Barocas JA. Incidence and Characteristics of Nonfatal Opioid Overdose Among Youths Aged 11 to 24 Years by Sex. JAMA Netw Open. 2020 Dec 1;3(12):e2030201. PMID: 33331919. PMC7747019.

Lim JK**, Earlywine JJ, Bagley SM, Marshall BDL, Hadland SE. Polysubstance Involvement in Opioid Overdose Deaths in Adolescents and Young Adults, 1999-2018. JAMA Pediatr. 2020 Nov 23. doi: 10.1001/jamapediatrics.2020.5035. Online ahead of print. PMID: 33226412. PMC7684514.

Earlywine JJ**, Hadland SE, Raifman J. State-level prescription drug monitoring program mandates and adolescent injection drug use in the United States, 1995-2017: A difference-in-differences analysis. PLoS Med. 2020 Sep 25;17(9):e1003272. PMID: 32976539. PMC7518580.

Hadland SE, Jent VA, Alinsky RH**, Marshall BDL, Mauro PM, Cerdá M. Opioid Use Disorder Treatment Facilities With Programs for Special Populations. Am J Prev Med. 2020;pii: S0749-3797(20)30178-1. PMID: 32448551. PMC1591965.

Hadland SE, Cerdá M, Earlywine JJ**, Krieger MS, Anderson TS**, Marshall BDL. Analysis of Pharmaceutical Industry Marketing of Stimulants, 2014 Through 2018. JAMA Pediatr. 2020 Jan 21. doi: 10.1001/jamapediatrics.2019.5526. [Epub ahead of print] PMID: 31961384. PMC6990909.

Alinsky RH**, Zima BT, Rodean J, Matson PA, Larochelle MR, Adger H Jr, Bagley SM, Hadland SE. Receipt of Addiction Treatment After Opioid Overdose Among Medicaid-Enrolled Adolescents and Young Adults. JAMA Pediatr. 2020;174(3):e195183. PMID: 31905233. PMC6990723.

Anderson TS**, Marshall BDL, Krieger MS, Cerdá M, Hadland SE. Financial Payments to Teaching Hospitals by Companies Marketing Opioids. J Gen Intern Med. 2019 Dec 17. doi: 10.1007/s11606-019-05596-1 [Epub ahead of print] PMID: 31848860. PMC7572903.

Chadi N**, Rodean J, Earlywine JJ, Zima BT, Bagley SM, Levy S, Hadland SE. Treatment for Nicotine Use Disorder Among Medicaid-Enrolled Adolescents and Young Adults. JAMA Pediatr. 2019;173(11):1103-5. PMID: 31545354. PMC6763988.

Hadland SE, Rivera-Aguirre A, Marshall BDL, Cerdá M. Association of Pharmaceutical Industry Marketing of Opioid Products With Mortality From Opioid-Related Overdoses. JAMA Netw Open. 2019 Jan 4;2(1):e186007. PMID: 30657529. PMC6484875.

Hadland SE, Cerdá M, Li Y, Krieger MS, Marshall BD. Pharmaceutical Industry Marketing of Opioid Products to Physicians and Subsequent Opioid Prescribing. JAMA Intern Med. 2018;178(6):861-863. PMID: 29799955. PMC6145750. Author reply: Hadland et al. JAMA Intern Med. 2018;178(10):1426-1427.

Hadland SE, Park TW, Bagley SM. Stigma associated with medication treatment for young adults with opioid use disorder: a case series. Addict Sci Clin Pract. 2018 May 7;13(1):15. PMID: 29730987. PMC5937046.

Hadland SE, Krieger MS, Marshall BD. Industry Payments to Physicians Involving Opioids, 2013-2015. Am J Public Health. 2017;107(9):1493-1495. PMID: 28787210. PMC5551628.

Hadland SE, Wharam JF, Schuster MA, Zhang F, Samet JH, Larochelle MR. Trends in Receipt of Buprenorphine and Naltrexone for Opioid Use Disorder among Adolescents and Young Adults, 2001-2014. JAMA Pediatr. 2017;171(8):747-755. PMID: 28628701. PMC5649381.

Hadland SE, Copelas SH, Harris SK. Trajectories of Substance Use Frequency among Adolescents Seen in Primary Care: Implications for Screening. J Pediatr. 2017;pii:S0022-3476(17)30143-9. PMID: 28196680. PMC5403571.

Hadland SE, Xuan Z, Sarda V, Blanchette J, Swahn MH, Heeren TC, Voas RB, Naimi TS. Alcohol Policies and Alcohol-Related Motor Vehicle Crash Fatalities Among Young People in the US. Pediatrics. 2017;139(3). pii: e20163037. PMID: 28193794. PMC5330403.

Hadland SE, Wood E, Dong H, Marshall BD, Kerr T, Montaner JS, DeBeck K. Suicide attempts and childhood maltreatment among street youth: a prospective cohort study. Pediatrics, 2015;136(3):440-9. PMID: 26240210. PMC4552091

Hadland SE, DeBeck K, Kerr T, Nguyen P, Simo A, Montaner JS, Wood E. Use of a medically supervised injection facility among street youth. J Adolesc Health, 2014;55(5):684-9. PMID: 24925493. PMC4209311.

Hadland SE, Harris SK. Youth marijuana use: State of the science for the practicing clinician. Curr Opin Pediatr, 2014;26(4):420-7. PMID: 24914878. PMC4138809

Google Scholar Analytics

Hadland SE, Cerdá M, Earlywine JJ, Krieger MS, Anderson TS, Marshall BDL. Analysis of Pharmaceutical Industry Marketing of Stimulants, 2014 Through 2018. JAMA Pediatr. 2020 Jan 21. doi: 10.1001/jamapediatrics.2019.5526. [Epub ahead of print] PMID: 31961384. PMC6990909.